Novo Nordisk ’s (NVO) share price has entered into oversold territory with an RSI value of 23.85. The Zacks Consensus Estimate on Novo Nordisk’s earnings for the full year period have moved higher by 16 cents over the past two months to $8.27 per share. Currently, Novo Nordisk is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (NVO) after its recent drop.
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment